Igan Biosciences, Shire deal

Igan granted Shire exclusive, worldwide rights to develop and commercialize preclinical IgA protease to treat IgA nephropathy, a rare kidney disorder. Geller Biopharm Inc. advised Igan. Igan declined to provide details, while Shire could not be reached for comment. ...